Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study
===========================================================================================

* Tom C. Russ
* Sarah E. Harris
* G. David Batty

## ABSTRACT

Dementia is a major global public health concern and in addition to recognised risk factors there is emerging evidence that poorer pulmonary function is linked with subsequent dementia risk. However, it is unclear if this observed association is causal or whether it might result from confounding. Therefore, we present the first two-sample Mendelian randomisation study of the association between pulmonary function and Alzheimer dementia using the most recent genome-wide association studies to produce instrumental variables for both. We found no evidence of a causal effect of reduced Forced Expiratory Volume in 1 second (FEV1) or Forced Vital Capacity (FVC) on Alzheimer dementia risk (both P>0.35). However, the FEV1/FVC ratio was associated with Alzheimer dementia risk with, in fact, superior function predicting an increased dementia risk (OR 1.12, 95%CI 1.02-1.23; P=0.016) which may result from survivor bias. While we can conclude that there is no causal link between impaired pulmonary function and Alzheimer dementia, our study sheds less light on potential links with other types of dementia.

Dementia is a major and growing global public health problem.1 The risk of Alzheimer disease is thought to be raised in the presence of a relatively small series of environmental and genetic factors. These include lower educational attainment, hypertension, obesity, diabetes, cigarette smoking, and the *APOE* ε4 allele.2

Recent findings from observational studies also suggest that impaired pulmonary function is consistently associated with a ∼40% evaluation in the risk of later dementia.3 While there is mechanistic evidence to support this association — including the hypoxic effect of extended sub-optimal ventilatory function4 — crucially, given the observational nature of these studies, it is unclear if this relationship is causal. An obstacle to drawing causal inference from such studies is the perennial problem of confounding —that, in the case of pulmonary function, the characteristics of people in the low functioning group differ from the unexposed in a variety of ways that may explain the association. Investigators attempt to include as many relevant covariates as possible but the possibility of confounding by unmeasured or imprecisely quantified factors is universal. Mendelian randomisation (MR) has been seen as a possible remedy to this problem5 and has been extended to a two-sample MR where genetic associations for the exposure and outcome are obtained from independent samples .6 Accordingly, for the first time to our knowledge, we present a two-sample MR study to clarify whether the observed association between poorer pulmonary function and subsequent Alzheimer dementia (AD) is causal.

## METHODS

We ran a two-sample MR using summary data from the UKBiobank/SpiroMeta Consortium Genome-Wide Association Study (GWAS) which comprised 400,102 individuals.7 We derived two genetic instruments for lung function: Forced Expiratory Volume in one second (litres; FEV1) and Forced Vital Capacity (litres; FVC). Of the 279 SNPs associated with lung function, but not smoking behaviour, only those related to the relevant trait with P<5×10−8 and the same direction of effect in UKBiobank and SpiroMeta were used as genetic instruments. In addition, we included a more exploratory measure — the FEV1/FVC ratio — which has been used in the diagnosis of chronic obstructive pulmonary disease whereby lower values are more suggestive of this condition.8 For the outcome we used summary data from the most recent GWAS which included 21,982 people with AD and 41,944 controls.9 The models used the TwoSampleMR R package.10 Since this study used publicly available data, no ethical approval was required.

## RESULTS

Table 1 shows the relationship between lung function and the subsequent risk of AD. There was no evidence of a causal effect of poorer lung function —using FEV1 or FVC — on AD risk (both P>0.35). However, each SD increase in FEV1/FVC ratio (indicating superior lung function) was associated with an increased AD risk (OR, 95%CI 1.12, 1.02-1.23; P=0.016). The MR Egger intercept for the latter indicates little horizontal pleiotropy (β=0.0002, P=0.96) and the inverse-variance weighted Q-value (177.7, P=0.08) suggests no substantial heterogeneity. Using the weighted median method gave a similar result (1.15, 1.00-1.31; P=0.048).

View this table:
[Table 1.](http://medrxiv.org/content/early/2020/09/30/2020.07.28.20163352/T1)

Table 1. 
Estimates of the association between pulmonary function (FEV1, FVC, and FEV1/FVC ratio) and Alzheimer dementia from a two-sample Mendelian randomization

## DISCUSSION

We found that the observed association between lower pulmonary function and AD risk was not supported as being causal in the present MR analyses. Thus, it is possible that the original relationship resulted from confounding by one or more unmeasured or poorly measured confounders. Multiple candidates exist including an adverse intrauterine environment leading to reduced maximal lung function, exposure to environmental factors (e.g., tobacco smoke, atmospheric pollution) affecting lung function and development, and socioeconomic factors (poverty, educational failure, and less-advantaged social class). In our systematic review and meta-analysis, most included studies took account of smoking and cardiovascular disease risk factors, and slightly fewer included height.3 Socioeconomic position was variably accounted for and there was little coverage of the whole life course in terms of all included covariables.

The FEV1 /FVC ratio has not been routinely examined in relation to dementia risk.3 However, we found a link between higher pulmonary function captured by this measure and increased AD risk. This may possibly be explained by survivor bias, with participants with poorer pulmonary function dying before they reach late life.

MR uses genetic variants which are randomly allocated at conception – and therefore generally independent of confounders that may otherwise bias the association of interest when using observational methods – as proxies for environmental exposures. This assumes that the genetic variants are: (1) associated with the exposure; (2) only associated with the outcome of interest via their effect on the exposure; and 3) independent of confounders. It also relies on the exposure being accurately measured in the GWAS from which the instrument is derived. Pulmonary function was accurately measured with rigorous quality control in both UKBiobank (87.2% participants) and the individual studies of the SpiroMeta consortium.7 It is unlikely that collider bias due to smoking and height adjustment in the lung function GWAS explains the observed association, as SNPs associated with smoking behaviour were excluded and a sensitivity analysis excluding the 12 SNPs included in our instrument which were associated with height in UKBiobank did not affect our conclusions. The AD GWAS included 46 case-control studies from four consortia.9 These studies used various methods of ascertaining dementia, with multiple diagnostic criteria being applied. Some studies used clinical diagnoses and some identified Alzheimer-type pathology post mortem. This variation is likely to affect the applicability of the GWAS findings in our analysis.

In contrast to the instrumental AD variable used here, most observational studies use a more general category of ‘dementia.’3,9 This lack of clarity is common and the multiple diseases which cause the dementia syndrome — such as Alzheimer disease, cerebrovascular disease, Lewy body disease, and Fronto-Temporal Lobar Degenerative syndromes — are frequently conflated. Depending on the methodology used to ascertain dementia status, clarifying an individual’s precise diagnosis can be challenging. For example, death certificates frequently only record the broad dementia syndrome. Thus, while we can conclude that there is no causal link between impaired pulmonary function and AD, our study sheds less light on potential links with other types of dementia. It is plausible that there may be a different relationship between pulmonary function and vascular dementia, for instance.

## Data Availability

All data are publicly available.

## Footnotes

*   **Funding:** This article received no specific funding. The Alzheimer Scotland Dementia Research Centre is funded by Alzheimer Scotland. The Lothian Birth Cohorts are funded by Age UK. TCR is employed by the UK National Health Service and the Scottish Government. GDB is supported by the UK Medical Research Council (MR/P023444/1) and the US National Institute on Aging (1R56AG052519-01; 1R01AG052519-01A1). All researchers are independent of their funders.

*   **Conflicts of interest:** none

*   Some clarification of the methods and results presented as ORs with 95% CIs.

*   Received July 28, 2020.
*   Revision received September 30, 2020.
*   Accepted September 30, 2020.


*   © 2020, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## REFERENCES

1.  1.Prince MJ, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina AM. World Alzheimer Report 2015. The Global Impact of Dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer’s Disease International; 2015.
    
    

2.  2.Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396(10248):413–446.
    
    

3.  3.Russ TC, Kivimaki M, Batty GD. Respiratory Disease and Lower Pulmonary Function as Risk Factors for Dementia: A Systematic Review With Meta-analysis. Chest. 2020.
    
    

4.  4.Horsburgh K, Wardlaw JM, van Agtmael T, et al. Small vessels, dementia and chronic diseases – molecular mechanisms and pathophysiology. Clinical Science. 2018;132(8):851–868.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToicHBjbGluc2NpIjtzOjU6InJlc2lkIjtzOjk6IjEzMi84Lzg1MSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIwLzA5LzMwLzIwMjAuMDcuMjguMjAxNjMzNTIuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

5.  5.Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? International Journal of Epidemiology. 2003;32(1):1–22.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/ije/dyg070&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12689998&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F09%2F30%2F2020.07.28.20163352.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000182341300001&link_type=ISI) 

6.  6.Hartwig FP, Davies NM, Hemani G, Davey Smith G. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. International Journal of Epidemiology. 2017;45(6):1717–1726.
    
    

7.  7.Shrine N, Guyatt AL, Erzurumluoglu AM, et al. New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. Nature Genetics. 2019;51(3):481–493.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41588-018-0321-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30804560&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F09%2F30%2F2020.07.28.20163352.atom) 

8.  8.Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–555.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1164/rccm.200703-456SO&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=17507545&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F09%2F30%2F2020.07.28.20163352.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000249646100004&link_type=ISI) 

9.  9.Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics. 2019;51(3):414–430.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41588-019-0358-2&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30820047&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F09%2F30%2F2020.07.28.20163352.atom) 

10. 10.Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLOS Genetics. 2017;13(11):e1007081.